(R)-2-(4-Ethyl-2,3-dioxopiperazine-1-carboxamido)-2-phenylacetic acid

Catalog No. :
ACZSIY285
CAS No. :
63422-71-9
Molecular Formula :
C15H17N3O5
Molecular Weight :
319.32

IUPAC Name:(R)-2-(4-ethyl-2,3-dioxopiperazine-1-carboxamido)-2-phenylacetic acid

(R)-2-(4-Ethyl-2,3-dioxopiperazine-1-carboxamido)-2-phenylacetic acid structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
25g98%$139.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(R)-2-(4-Ethyl-2,3-dioxopiperazine-1-carboxamido)-2-phenylacetic acid
IUPAC Name(R)-2-(4-ethyl-2,3-dioxopiperazine-1-carboxamido)-2-phenylacetic acid
MDL No.MFCD00799536
Molecular FormulaC15H17N3O5
Molecular Weight319.32
SMILESO=C(O)[C@H](NC(N1C(C(N(CC)CC1)=O)=O)=O)C2=CC=CC=C2
InChI KeyJQEHQELQPPKXRR-LLVKDONJSA-N
SynonymCS-0151993 | A834367 | (R)-(-)- alpha -[[(4-Ethyl-2,3-dioxo-1-piperazinyl)carbonyl]amino]benzeneacetic acid | EPCP | SCHEMBL7828421 | (R)-(((4-Ethyl-2,3-dioxopiperazin-1-yl)carbonyl)amino)phenylaceticacid | s10945 | AC-8403 | UNII-YG582EF7NG | AKOS0158957
CAS No.63422-71-9
PubChem CID2733658

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H315-H319
Precautionary Statement(s)
P264-P280-P302+P352+P332+P313+P362+P364-P305+P351+P338+P337+P313

Synthetic Route by SureRoute

1. ACZSIY285 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACZSIY285 route product structure diagram
    ACZSIY28563422-71-9 In Stock
Inquiry

2. ACZSIY285 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACLRKA857 route compound structure diagram
    ACLRKA857875-74-1 In Stock
  4. Then
  5. ACZSIY285 route product structure diagram
    ACZSIY28563422-71-9 In Stock
Inquiry

Comments (0)